HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N- (3- isopropyl- 3- ((4- (4- (trifluoromethyl)pyridin- 2- yl)piperazin- 1- yl)carbonyl)cyclopentyl)- 3- methoxytetrahydro- 2H- pyran- 4- amine

structure in first source

Also Known As:

INCB 10820; INCB-10820; INCB10820; PF 4178903; PF-4178903; PF4178903

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrans: 130
    - N-(3-isopropyl-3-((4-(4-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)carbonyl)cyclopentyl)-3-methoxytetrahydro-2H-pyran-4-amine: 1
  - Piperazines: 26
    - N-(3-isopropyl-3-((4-(4-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)carbonyl)cyclopentyl)-3-methoxytetrahydro-2H-pyran-4-amine: 1

Experts

1.	Chung, Choon Hee: 1 article (01/2018)
2.	Huh, Ji Hye: 1 article (01/2018)
3.	Kim, Hong Min: 1 article (01/2018)
4.	Ko, Hyun-Jeong: 1 article (01/2018)
5.	Kwon, Mi Hye: 1 article (01/2018)
6.	Lee, Bo Ra: 1 article (01/2018)
7.	Lee, Eun Soo: 1 article (01/2018)

Related Diseases

1.	Glucose Intolerance 01/01/2018 - "PF4178903 treatment significantly improved HFD-induced insulin resistance and glucose intolerance. "
2.	Insulin Resistance 01/01/2018 - "PF4178903 treatment significantly improved HFD-induced insulin resistance and glucose intolerance. " 01/01/2018 - "Here, the effect of PF4178903, a dual CCR2/CCR5 antagonist, on obesity and insulin resistance was evaluated. "
3.	Obesity 01/01/2018 - "Here, the effect of PF4178903, a dual CCR2/CCR5 antagonist, on obesity and insulin resistance was evaluated. "
4.	Body Weight (Weight, Body) 01/01/2018 - "After treatment with PF4178903, both body weight and adipocyte size in white adipose tissue were decreased in HFD-fed mice. "

Related Therapies and Procedures

1.	Aftercare (After-Treatment)